The utility of MRI in suspected MS
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Citation Manager Formats
Make Comment
See Comments

Abstract
Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently, confirmation of the diagnosis of MS has generally required the demonstration of clinical activity that is disseminated in both time and space. Nevertheless, with the advent of MRI techniques, occult disease activity can be demonstrated in 50 to 80% of patients at the time of the first clinical presentation. Prospective studies have shown that the presence of such lesions predicts future conversion to clinically definite (CD) MS. Indeed, in a young to middle-aged adult with a clinically isolated syndrome (CIS), once alternative diagnoses are excluded at baseline, the finding of three or more white matter lesions on a T2-weighted MRI scan (especially if one of these lesions is located in the periventricular region) is a very sensitive predictor (>80%) of the subsequent development of CDMS within the next 7 to 10 years. Moreover, the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up scans are also highly predictive of the subsequent development of CDMS in the near term. By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely.
- Received December 12, 2002.
- Accepted May 29, 2003.
Disputes & Debates: Rapid online correspondence
- The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subc.
- B.M. J. Uitdehaag, VU Medical Centre, Amsterdam, bmj.uitdehaag@vumc.nl
- J.J.G. Geuerts, F. Barkhof, C.H. Polman
Submitted April 20, 2004 - Reply to Uitdehaag et al
- Douglas S. Goodin, MD, Chair, TTA Subcommittee, wedlund@aan.com
- Elliot M. Frohman, MD, PhD
Submitted April 20, 2004 - The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommitte
- Elliot M. Frohman, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390elliot.frohman@utsouthwestern.edu
Submitted October 13, 2003 - The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommitte
- James M Gordon, 1570 N 115th St., Suite 14, Seattle, WA 98133jgordon@nwhsea.org
Submitted October 13, 2003
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.